How does Gedatolisib actually stop cancer cells from growing?
Gedatolisib blocks two key growth proteins (PI3K and mTOR) inside cancer cells, which stops them from dividing and surviving. In the VIKTORIA-1 trial, 68% of women with advanced breast cancer saw their tumors shrink when Gedatolisib was combined with fulvestrant and palbociclib [1].
Cancer cells have a 'growth accelerator' called the PI3K/mTOR pathway. Gedatolisib is like a brake pedal that shuts down this pathway. The VIKTORIA-1 trial (2026) showed that when Gedatolisib was added to fulvestrant and palbociclib, 68% of women had their tumors shrink, compared to only 48% on fulvestrant alone [1].
Inside your body, Gedatolisib travels through your bloodstream and enters cancer cells. It sticks to the PI3K and mTOR proteins and locks them up, so the cancer cell can't receive the 'grow' signal. Your healthy cells have backup growth pathways, so they survive better than the cancer cells do [4].
The drug is given as a 180 mg IV infusion every 2 weeks. Your body clears it quickly—about 89% leaves through your urine within 72 hours, so it doesn't build up in your system [4]. This fast clearance is why you need regular infusions to keep the brake on cancer growth.
Ask your oncologist: 'Does my tumor have a PIK3CA mutation?' If yes, Gedatolisib may work better for you. If no, your doctor may recommend a different combination. This one question can save you months of ineffective treatment [1].